Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$41.09 USD

41.09
29,395,143

+0.84 (2.09%)

Updated May 31, 2024 03:59 PM ET

After-Market: $41.13 +0.04 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Why Fusion Pharmaceuticals (FUSN) Stock Was Up 14% on Wednesday

by Zacks Equity Research

Fusion Pharmaceuticals (FUSN) surges to a new record level 52-week high after analysts at Raymond James upgraded its rating following the buyout announcements for two comparable companies.

Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets Goals

by Zacks Equity Research

Cytokinetics (CYTK) reports positive results from its pivotal late-stage study of aficamten in symptomatic obstructive hypertrophic cardiomyopathy patients. The stock rallies 83% in response.

Ekta Bagri headshot

Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data

by Ekta Bagri

Bristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively.

FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras

by Zacks Equity Research

Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.

AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion

by Zacks Equity Research

AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.

Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B

by Zacks Equity Research

Bristol Myers (BMY) is set to acquire RayzeBio for $4.1 billion to strengthen and diversify its already established oncology portfolio. The transaction is expected to close in the first half of 2024.

Company News for Dec 27, 2023

by Zacks Equity Research

Companies In The Article Are: INTC,RYZB,BMY,NIO,MANU

Mark Vickery headshot

Yes Virginia, There Is a Santa Claus Rally

by Mark Vickery

The Russell is up an astounding +26% from late October, largely thanks to signaled interest rate cuts from the Fed in 2024.

Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers

by Zacks Equity Research

Bristol Myers (BMY) is set to acquire Karuna (KRTX) for $330 per share. This transaction is expected to close in the first half of 2024.

Company News for Dec 26, 2023

by Zacks Equity Research

Companies In The Articles: KRTX, BMY, NKE, TCEHY, RKLB

Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B

by Zacks Equity Research

Bristol Myers (BMY) announces a second acquisition in two months. It is set to buy Karuna Therapeutics, Inc. (KRTX) for $14 billion to strengthen its neuroscience portfolio.

Bristol Myers Squibb (BMY) Rises But Trails Market: What Investors Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.26, marking a +0.59% move from the previous day.

Ekta Bagri headshot

3 Cancer-Focused Biotechs That Appear Promising Bets for 2024

by Ekta Bagri

With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.

The Zacks Analyst Blog Highlights Microsoft, Booking Holdings, Bristol-Myers Squibb, Equifax hand First Solar

by Zacks Equity Research

Microsoft, Booking Holdings, Bristol-Myers Squibb, Equifax hand First Solar are included in this Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Microsoft, Booking Holdings & Bristol-Myers Squibb

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Booking Holdings Inc. (BKNG) and Bristol-Myers Squibb Company (BMY).

Nalak Das headshot

5 Stocks to Watch on Their Recent Dividend Hike

by Nalak Das

Five stocks that have recently raised dividends are: BMY, PWR, CARR, AVGO, OC.

Bristol Myers (BMY) Stops Late-Stage Colorectal Cancer Study

by Zacks Equity Research

Bristol Myers (BMY) decides to discontinue the phase III colorectal cancer study as it was unlikely to meet its primary endpoints upon completion.

Bristol Myers Squibb (BMY) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.47, marking a -0.75% move from the previous day.

Bristol Myers (BMY) Partners With SystImmune for Oncology Drug

by Zacks Equity Research

Bristol Myers (BMY) is set to co-develop and co-commercialize oncology candidate BL-B01D1 in the United States with SystImmune.

Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $50.31 in the latest trading session, marking a +0.3% move from the prior day.

Will Bristol Myers' (BMY) Efforts to Boost Portfolio be Enough?

by Zacks Equity Research

Shares of Bristol Myers (BMY) have been impacted by pipeline bottlenecks and its key drugs face generic competition. We take a look at the company's efforts to counter these.

Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data

by Zacks Equity Research

Updates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week.

Bristol Myers' (BMY) Opdivo sBLA Gets FDA's Priority Review

by Zacks Equity Research

Bristol Myers (BMY) announces that the FDA has accepted its sBLA for Opdivo to treat first-line adult patients with unresectable or metastatic bladder cancer under priority review.

Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study

by Zacks Equity Research

Exelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC.

AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion

by Zacks Equity Research

AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors and hematologic malignancies.